Table 1.
Baseline characteristics of patients (n = 55)
| Variables* | Patients |
|---|---|
| N (%) | 55 (100) |
| Age, mean ± SD, years | 46.4 ± 9.9 |
| Female gender, n (%) | 37 (67.3) |
| Vaccination-associated cases, n (%) | 16 (29.1) |
| Inactivated COVID-19 vaccine-associated | 10 (62.5) |
| mRNA COVID-19 vaccine-associated | 6 (37.5) |
| Post-vaccination symptom onset time, median (range), days | 6.5 (2.0–20.0) |
| Time to diagnosis, median (range), days | 29 (8–90) |
| Thyroid hormone status at diagnosis, n (%) | |
| Hyperthyroid | 39 (70.9) |
| Subclinical hyperthyroid | 6 (10.9) |
| Euthyroid | 10 (18.2) |
| TSH, median (range), mIU/L | 0.02 (0.01–3.92) |
| fT4, median (range), pmol/L | 28.32 (12.10–88.04) |
| WBC, median (range), 103/mm3 | 9.30 (5.10–16.7) |
| ESR, mean ± SD, mm/h | 47.1 ± 18.8 |
| CRP, median (range), mg/L | 49.0 (5.7–224.0) |
| Disease involvement, n (%) | |
| Unilateral | 23 (41.8) |
| Bilateral | 32 (58.2) |
| Thyroid volume at diagnosis, median (range), cm3 | 19.25 (7.49–101.67) |
| Treatment modality, n (%) | |
| NSAIDs | 23 (41.8) |
| Methylprednisolon | 32 (58.2) |
| Follow-up time, mean ± SD, days (n = 45) | 47.4 ± 19.4 |
CRP C-reactive protein; ESR erythrocyte sedimentation rate; fT4 free, thyroxine; NSAIDs non-steroidal anti-inflammatory drugs; TSH thyroid-stimulating hormone; WBC white blood cells; SD standard deviation
*Normally distributed data are reported using mean ± standard deviation, while non-normally distributed data are reported using median (min–max)